Literature DB >> 11257018

Penicillin pharmacodynamics in four experimental pneumococcal infection models.

H Erlendsdottir1, J D Knudsen, I Odenholt, O Cars, F Espersen, N Frimodt-Møller, K Fuursted, K G Kristinsson, S Gudmundsson.   

Abstract

Clinical and animal studies indicate that with optimal dosing, penicillin may still be effective against penicillin-nonsusceptible pneumococci (PNSP). The present study examined whether the same strains of penicillin-susceptible pneumococci (PSP) and PNSP differed in their pharmacodynamic responses to penicillin by using comparable penicillin dosing regimens in four animal models: peritonitis, pneumonia, and thigh infection in mice and tissue cage infection in rabbits. Two multidrug-resistant isolates of Streptococcus pneumoniae type 6B were used, one for which the penicillin MIC was 0.016 microg/ml and the other for which the penicillin MIC was 1.0 microg/ml. Two additional strains of PNSP were studied in the rabbit. The animals were treated with five different penicillin regimens resulting in different maximum concentrations of drugs in serum (C(max)s) and times that the concentrations were greater than the MIC (T(>MIC)s). The endpoints were bacterial viability counts after 6 h of treatment in the mice and 24 h of treatment in the rabbits. Similar pharmacodynamic effects were observed in all models. In the mouse models bactericidal activity depended on the T(>MIC) and to a lesser extent on the Cmax/MIC and the generation time but not on the area under the concentration-time curve (AUC)/MIC. Maximal bactericidal activities were similar for both PSP and PNSP, being the highest in the peritoneum and blood (approximately 6 log10 CFU/ml), followed by the thigh (approximately 3 log10 CFU/thigh), and being the lowest in the lung (approximately 1 log10 CFU/lung). In the rabbit model the maximal effect was approximately 6 log10 CFU/ml after 24 h. In the mouse models bactericidal activity became marked when T(>MIC) was > or =65% of the experimental time and C(max) was > or =15 times the MIC, and in the rabbit model bactericidal activity became marked when T(>MIC) was > or =35%, Cmax was > or =5 times the MIC, and the AUC at 24 h/MIC exceeded 25. By optimization of the Cmax/MIC ratio and T(>MIC), the MIC of penicillin for pneumococci can be used to guide therapy and maximize therapeutic efficacy in nonmeningeal infections caused by PNSP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257018      PMCID: PMC90427          DOI: 10.1128/AAC.45.4.1078-1085.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.

Authors:  K Tateda; K Takashima; H Miyazaki; T Matsumoto; T Hatori; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Pharmacodynamics of penicillin are unaffected by bacterial growth phases of Streptococcus pneumoniae in the mouse peritonitis model.

Authors:  J D Knudsen; N Frimodt-Møller; F Espersen
Journal:  J Antimicrob Chemother       Date:  1998-04       Impact factor: 5.790

3.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

4.  An in vivo model for evaluation of the postantibiotic effect.

Authors:  I Odenholt; S E Holm; O Cars
Journal:  Scand J Infect Dis       Date:  1988

5.  The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth.

Authors:  E Tuomanen; R Cozens; W Tosch; O Zak; A Tomasz
Journal:  J Gen Microbiol       Date:  1986-05

6.  Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study.

Authors:  S Einarsson; M Kristjansson; K G Kristinsson; G Kjartansson; S Jonsson
Journal:  Scand J Infect Dis       Date:  1998

7.  Relevance of the Alexander Project: pharmacodynamic considerations.

Authors:  G L Drusano; F W Goldstein
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

8.  Static and dynamic properties of tissue cage fluid in rabbits.

Authors:  A M Bergholm; C Henning; S E Holm
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

9.  Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins.

Authors:  N Frimodt-Møller; M W Bentzon; V F Thomsen
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

Review 10.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

View more
  17 in total

1.  Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models.

Authors:  Jenny Dahl Knudsen; Inga Odenholt; Helga Erlendsdottir; Magnus Gottfredsson; Otto Cars; Niels Frimodt-Møller; Frank Espersen; Karl G Kristinsson; Sigurdur Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 2.  Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Authors:  Marilyn N Martinez; Mark G Papich; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

3.  H3 Propranolol serum levels following lidocaine administration in rats with CCL4 induced liver damage.

Authors:  A Kotsiou; M Tsamouri; S Anagnostopoulou; M Tzivras; E Vairactaris; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

4.  Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model.

Authors:  I Gustafsson; E Löwdin; I Odenholt; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Antibiotic selection of Escherichia coli sequence type 131 in a mouse intestinal colonization model.

Authors:  Frederik Boetius Hertz; Anders Løbner-Olesen; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

6.  Identification of a conserved chromosomal region encoding Klebsiella pneumoniae type 1 and type 3 fimbriae and assessment of the role of fimbriae in pathogenicity.

Authors:  Carsten Struve; Martin Bojer; Karen Angeliki Krogfelt
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

7.  Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model.

Authors:  Inga Odenholt; Ingegerd Gustafsson; Elisabeth Löwdin; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.

Authors:  Alasdair P MacGowan; Alan R Noel; Chris A Rogers; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

9.  Characterization of Klebsiella pneumoniae type 1 fimbriae by detection of phase variation during colonization and infection and impact on virulence.

Authors:  Carsten Struve; Martin Bojer; Karen Angeliki Krogfelt
Journal:  Infect Immun       Date:  2008-06-16       Impact factor: 3.441

10.  Anticoagulant-induced changes on antibiotic concentrations in the serum and bones.

Authors:  A Kotsiou; E Diamanti; A Potamianou; H Parara; J Vovou; C Perisanidis; C Tes; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.